RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $258
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Outperform and raises the price target from $195 to $258.